Results 71 to 80 of about 67,058 (255)

Myelodysplastic syndrome occurring after enfortumab vedotin treatment for metastatic urothelial carcinoma

IJU Case Reports
Introduction Enfortumab vedotin is an antibody‐drug conjugate targeting Nectin‐4 for the treatment of advanced urothelial carcinoma in patients previously treated with platinum‐containing chemotherapy and immune checkpoint inhibitors.
Kazuki Yanagida, Taketo Kawai, Toyoshi Seito, Kensuke Matsumoto, Tomoyuki Kaneko, Tohru Nakagawa   +5 more
doaj   +1 more source

Tumor suppressor p53 protein expression: prognostic significance in patients with low-risk myelodysplastic syndrome

Revista Brasileira de Hematologia e Hemoterapia, 2014
BACKGROUND: At the time of diagnosis, more than 50% of patients with myelodysplastic syndrome have a normal karyotype and are classified as having a favorable prognosis. However, these patients often show very variable clinical outcomes.
Fernando Barroso Duarte, Romelia Pinheiro Gonçalves, Maritza Cavalcante Barbosa, Francisco Dário Rocha Filho, Talyta Ellen de Jesus dos Santos, Thayna Nogueira dos Santos, Paulo Roberto Leitão de Vasconcelos   +6 more
doaj   +1 more source

Pyoderma Gangrenosum: A Retrospective Cohort Study of Comorbidities and Therapies in Over 65,000 Patients in the TriNetX Database

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis associated with systemic inflammatory diseases and malignancy. Although biologic therapies demonstrate efficacy in PG, the extent of their real‐world use remains incompletely characterized.
Rhiannon Grange, Tara Sholji, Marra Aghajani, Cindy Kok, John Frew   +4 more
wiley   +1 more source

Impact of Co‐Morbid Immunocompromise in HPV‐Associated Oropharyngeal Squamous Cell Carcinoma

The Laryngoscope, EarlyView.
Among patients with surgically resected Human Papillomavirus positive (HPV+) oropharyngeal squamous cell carcinoma (OPSCC), immunocompromised patients had significantly worse overall survival compared to the non‐compromised group; however, these exploratory findings should be interpreted cautiously.
Maxwell L. Weng, Tereza Vitkovska, Song Hon Hwang, Lauran K. Evans, Hong‐Ho Yang, Christopher Dann, Dipti Sajed, Maie A. St. John   +7 more
wiley   +1 more source

Cost of the treatment of myelodisplastic syndrome in Brazil

Revista Brasileira de Hematologia e Hemoterapia, 2011
INTRODUCTION: Myelodysplastic syndrome is an incurable and rare hematological disease that affects the production of blood cells. One aim of treatment is to maintain the blood-cell count to near-normal levels.
Otávio Clark, Enéas José de Matos Faleiros   +1 more
doaj   +1 more source

Information Design for Early‐Stage Dose‐Finding Trials

Naval Research Logistics (NRL), EarlyView.
ABSTRACT To enhance enrollment rates in early‐stage dose‐finding clinical trials, we propose an information design approach, where the clinical investigator (CI) commits to an information releasing mechanism (IRM) based on the treatment's uncertain efficacy and toxicity to encourage patients to participate in the trial.
Amin Khademi, Ningyuan Chen
wiley   +1 more source

Myelodysplasia followed by Good's Syndrome: A unique manifestation associated with thymoma

Kaohsiung Journal of Medical Sciences, 2012
Good’s syndrome, also known as thymoma with combined immunodeficiency, is rare. The immunodeficiency may precede, arise concurrently with or follow the diagnosis of thymoma.
Ling-Ping Chen, Jui-Shan Tsai, Wei-Ming Lai, Ling-Jung Yen, Ming-Sun Yu, Shyh-Jer Lin   +5 more
doaj   +1 more source

Retrospective evaluation of palliative care consultation in critically ill adult and pediatric cancer subjects

Pediatric Investigation, EarlyView.
Children with cancer received more palliative care consultation before, but fewer during, critical illness compared with adults. This disparity suggests underuse of palliative care during pediatric critical care. ABSTRACT Importance Palliative care consultation is an essential component of comprehensive care for patients with cancer during critical ...
Conrad Krawiec, Neal Thomas
wiley   +1 more source

Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation

Haematologica, 2009
Background After successful treatment of malignant diseases, therapy-related myelodysplastic syndrome and acute myeloid leukemia have emerged as significant problems.Design and Methods The aim of this study was to investigate outcome and risk factors in ...
Nicolaus Kröger, Ronald Brand, Anja van Biezen, Axel Zander, Judith Dierlamm, Dietger Niederwieser, Agnès Devergie, Tapani Ruutu, Jackie Cornish, Per Ljungman, Alois Gratwohl, Catherine Cordonnier, Dietrich Beelen, Eric Deconinck, Argiris Symeonidis, Theo de Witte, for the Myelodysplastic Syndromes Subcommittee of The Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)   +16 more
doaj   +1 more source

Semi‐mechanistic population PK/PD model to aid clinical understanding of myelodysplastic syndromes following treatment with Venetoclax and Azacitidine

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 448-459, March 2025.
Abstract Myelodysplastic syndromes (MDS) represent a group of bone marrow disorders involving cytopenias, hypercellular bone marrow, and dysplastic hematopoietic progenitors. MDS remains a challenge to treat due to the complex interplay between disease‐induced and treatment‐related cytopenias.
Neha Thakre, Corinna Maier, Jiuhong Zha, Benjamin Engelhardt, Johannes E. Wolff, Sven Mensing   +5 more
wiley   +1 more source